BioPharmSignal logoBioPharmSignal

Biotech News

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

Minerva Neuroscience (NERV)Minerva NeuroscienceEarnings

Confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia initiated and first patient screened Previous open label trial data presented at SIRS 2026 showed no safety or drug–drug interaction concerns with roluperidone and olanzapine Roluperidone remains the only late-stage

Open original release

Related news

BTAIBioXcel2026-05-15 11:00 EST

BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results

GHRSGH Research2026-05-14 11:00 EST

GH Research Reports First Quarter 2026 Financial Results and Provides Business Update

ABOSAcumen Pharmaceuticals2026-05-12 11:00 EST

Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights

ANNXAnnexon, Inc.2026-05-07 20:01 EST

Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones

DNLIDenali Therapeutics2026-05-07 20:01 EST

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

PRAXPraxis Precision Medicines2026-05-07 12:00 EST

Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2026 Financial Results

TSHATaysha Gene Therapies2026-05-06 12:00 EST

Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update

PRAXPraxis Precision Medicines2026-05-04 20:01 EST

Praxis Precision Medicines to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026, and Participate in Upcoming Investor Conference

TSHATaysha Gene Therapies2026-04-29 12:00 EST

Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6

NBIXNeurocrine Biosciences2026-04-14 20:01 EST

Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2026 Financial Results

View all latest news

Minerva Neuroscience

Minerva Neurosciences is a neuroscience company focused on psychiatric and CNS disorders. Its pipeline has centered on difficult brain-health programs with high unmet need.

Recent company news

NERVMinerva Neuroscience2026-06-01 20:05 EST

Minerva Neurosciences Establishes Scientific Advisory Board to Advance Development of Roluperidone and Future Pipeline Programs

NERVMinerva Neuroscience2026-05-18 20:05 EST

Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference

NERVMinerva Neuroscience2026-05-05 12:00 EST

Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates

NERVMinerva Neuroscience2026-04-02 20:05 EST

Minerva Announces Leadership Transition

NERVMinerva Neuroscience2026-03-31 20:05 EST

Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Stock data

Close
4.21 USD
Market cap
221.3M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States